Off-Label Is Off The Docket: Supreme Court Leaves RU-486 Flexibility Intact
This article was originally published in The Pink Sheet Daily
Executive Summary
High court declines to intervene in dispute over Arizona law that would restrict use of abortion drug; court also denies Roche petition for review of Boniva patent ruling.
You may also be interested in...
Abortion Pills Offered Nonprescription By E-Commerce Firms FDA Warned
One active ingredient in unapproved drugs sold by two e-commerce operations, identified by FDA as Rabold and AidAccess.org, is mifepristone, also known as RU-486 in the only drug with the ingredient approved for an indication of medical termination of early pregnancy, Danco Laboratories' Mifeprex. Firms' websites offer sales of products without requiring customers to submit prescriptions.
Pharma Strikes Out At Supreme Court As Three Recent Cert Petitions Fail
Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.